BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Why the chemtrail conspiracy theory lingers and grows – and why Tucker Carlson is talking about it - 2Going with Children: Tips for Tranquil Family Get-aways
- 3Supercharge Your Remote Work Arrangement with These Game-Changing Instruments
- 4The Way to Fruitful Weight reduction: Individual Wellbeing Excursions
- 510 Natural products to Remember for Your Eating routine for a Better You
- Vote in favor of your Favored kind of craftsmanship
- Ocean side Locations for a Family Excursion
- Ethiopian earthquakes and volcanic eruptions: earth scientist explains the link
- Grasping the Basics of Business Land Regulation
- Instructions to Pick the Best Course for Your Next Waterway Voyage: Objections, Views, and Social Encounters
- Dr. Vinay Prasad's memo raises concerns about COVID-19 vaccines and pediatric mortality
- The most effective method to Oversee Unsold SUVs in the Car Business
- Instructions to Keep an Inspirational perspective After Cellular breakdown in the lungs Treatment
- 'The Beast in Me' arrives on Netflix: Is it based on a true story? And what drew Claire Danes to it? What to know about the thriller series.
